Emerging Therapeutic Treatments for Multidrug-Resistant Bacteria: A Review
DOI:
https://doi.org/10.54097/p98n9f69Keywords:
Phage Therapy, CRISPR/CAS, Nanoparticles, Multidrug-resistant Bacteria, Nano-Drug Delivery Systems (nano-DDS)Abstract
The rapid rise of multidrug-resistant (MDR) bacteria poses a severe global health threat, rendering many conventional antibiotics ineffective and contributing to increased morbidity, mortality, and healthcare costs. In response to this escalating crisis, novel antimicrobial strategies are being explored, including bacteriophage therapy, CRISPR-Cas systems, and nanoparticle-based therapeutics. This review examines these innovative approaches' mechanisms, clinical progress, and limitations in combating MDR pathogens, particularly the WHO-prioritized ESKAPE group. Bacteriophages offer strain-specific bacterial killing with minimal off-target effects, but regulatory uncertainty, immune responses, and narrow host ranges hinder their use. CRISPR-Cas systems provide precise gene-editing capabilities to eliminate resistance genes or target specific bacterial strains, though concerns about off-target effects, delivery systems, and biosafety remain unresolved. Nanoparticles, including silver and gold NPs, and nano-drug delivery systems exhibit broad-spectrum antimicrobial properties and targeted delivery potential but raise cytotoxicity, standardization, and long-term safety issues. Despite their promise, each strategy faces critical challenges that must be addressed before clinical translation is viable. Integrating these therapies, alongside continued research, ethical oversight, and global collaboration, may offer a sustainable and adaptable solution to the growing burden of antimicrobial resistance.
Downloads
References
[1] De Kraker MEA, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year Due to Antimicrobial Resistance by 2050? PLoS Medicine. 2016 Nov 29;13(11):e1002184. Available from: https://doi.org/10.1371/journal.pmed.1002184.
[2] Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Jan 19;399(10325):629–55. Available from: https://doi.org/10.1016/s0140-6736(21)02724-0.
[3] O RMI, A BS. Mechanisms of Antibiotic Resistance in Bacteria: A review. African Journal of Pharmaceutical Sciences. 2024 Mar 5;4(1):1–12. Available from: https://doi.org/10.51483/afjps. 4.1. 2024.1-12.
[4] De Lencastre H, Oliveira D, Tomasz A. Antibiotic-resistant Staphylococcus aureus: a paradigm of adaptive power. Current Opinion in Microbiology. 2007 Oct 1;10(5):428–35. Available from: https://doi.org/ 10. 1016/j.mib.2007.08.003.
[5] Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. The Lancet Infectious Diseases. 2018 Nov 5;19(1):56–66. Available from: https://doi.org/10.1016/s1473-3099(18)30605-4.
[6] Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. eLife. 2016 Sep 5;5. Available from: https://doi.org/10.7554/elife.18082.
[7] Weinbauer MG. Ecology of prokaryotic viruses. FEMS Microbiology Reviews. 2003 Oct 28;28(2):127–81. Available from: https://doi.org/10.1016/j.femsre.2003.08.001.
[8] Rasool MH, Yousaf R, Siddique AB, Saqalein M, Khurshid M. Isolation, Characterization, and Antibacterial Activity of Bacteriophages Against Methicillin-Resistant Staphylococcus aureus in Pakistan. Jundishapur Journal of Microbiology. 2016 Sep 18;9(10). Available from: https://doi.org/10. 5812/ jjm. 36135.
[9] Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Critical Care. 2017 Jun 4;21(1). Available from: https://doi.org/10. 1186/ s13054-017-1709-y.
[10] Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiology Letters. 2015 Dec 20;363(3):fnv242. Available from: https://doi.org/10.1093/ femsle/ fnv242.
[11] Lossouarn J, Beurrier E, Bouteau A, Moncaut E, Silmane MS, Portalier H, et al. The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method. Antimicrobial Agents and Chemotherapy. 2024 Apr 9;68(5). Available from: https://doi.org/10.1128/aac.01439-23.
[12] Little JS, Dedrick RM, Freeman KG, Cristinziano M, Smith BE, Benson CA, et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nature Communications. 2022 May 3;13(1). Available from: https://doi.org/10.1038/s41467-022-29689-4.
[13] Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. The Journal of Infection in Developing Countries. 2014 Feb 12;8(02):129–36. Available from: https://doi.org/10.3855/jidc.3573.
[14] Buckling A, Rainey PB. Antagonistic coevolution between a bacterium and a bacteriophage. Proceedings of the Royal Society B Biological Sciences. 2002 May 7;269(1494):931–6. Available from: https://doi. org/ 10.1098/rspb.2001.1945.
[15] Kifelew LG, Warner MS, Morales S, Thomas N, Gordon DL, Mitchell JG, et al. Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. Viruses. 2020 May 18;12(5):559. Available from: https://doi.org/10.3390/v12050559.
[16] Ozkan, I., Akturk, E., Yeshenkulov, N., Atmaca, S., Rahmanov, N., & Atabay, H. I. (2016). Lytic activity of various phage cocktails on multidrug-resistant bacteria. Clinical and Investigative Medicine, 39(6), S66-S70.
[17] Yang Q, Le S, Zhu T, Wu N. Regulations of phage therapy across the world. Frontiers in Microbiology. 2023 Oct 6;14. Available from: https://doi.org/10.3389/fmicb.2023.1250848.
[18] Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan PT, Venketesan R. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. Nanomedicine, Nanotechnology, Biology, and Medicine. 2009 May 16;6(1):103–9. Available from: https://doi.org/10.1016/j.nano.2009.04.006.
[19] Rai A, Prabhune A, Perry CC. Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings. Journal of Materials Chemistry. 2010 Jan 1;20(32):6789. Available from: https://doi.org/10.1039/c0jm00817f.
[20] Gupta A, Mumtaz S, Li CH, Hussain I, Rotello VM. Combating antibiotic-resistant bacteria using nanomaterials. Chemical Society Reviews. 2018 Nov 21;48(2):415–27. Available from: https://doi.org/ 10. 1039/ c7cs00748e.
[21] Andrade F, Rafael D, Videira M, Ferreira D, Sosnik A, Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Advanced Drug Delivery Reviews. 2013 Aug 7;65(13–14):1816–27. Available from: https://doi.org/10.1016/j.addr.2013.07.020.
[22] Kaur S, Kumari A, Negi AK, Galav V, Thakur S, Agrawal M, et al. Nanotechnology based approaches in phage therapy: Overcoming the pharmacological barriers. Frontiers in Pharmacology. 2021 Oct 5;12. Available from: https://doi.org/10.3389/fphar.2021.699054.
[23] Nieth A, Verseux C, Barnert S, Süss R, Römer W. A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opinion on Drug Delivery. 2015 May 2;12(9):1411–24. Available from: https://doi.org/10.1517/17425247.2015.1043125.
[24] Baptista PV, McCusker MP, Carvalho A, Ferreira DA, Mohan NM, Martins M, et al. Nano-Strategies to fight Multidrug Resistant Bacteria—“A Battle of the Titans.” Frontiers in Microbiology. 2018 Jul 2;9. Available from: https://doi.org/10.3389/fmicb.2018.01441.
[25] Bikard D, Barrangou R. Using CRISPR-Cas systems as antimicrobials. Current Opinion in Microbiology. 2017 Jun 1; 37:155–60. Available from: https://doi.org/10.1016/j.mib.2017.08.005.
[26] Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. Programmable removal of bacterial strains by use of Genome-Targeting CRISPR-CAS systems. mBio. 2014 Jan 29;5(1). Available from: https://doi.org/10.1128/mbio.00928-13.
[27] Junaid M, Thirapanmethee K, Khuntayaporn P, Chomnawang MT. CRISPR-Based Gene Editing in Acinetobacter baumannii to Combat Antimicrobial Resistance. Pharmaceuticals. 2023 Jun 23;16(7):920. Available from: https://doi.org/10.3390/ph16070920.
[28] Bikard D, Barrangou R. Using CRISPR-Cas systems as antimicrobials. Current Opinion in Microbiology. 2017 Jun 1;37:155–60. Available from: https://doi.org/10.1016/j.mib.2017.08.005.
[29] Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, et al. Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections. Antimicrobial Agents and Chemotherapy. 2003 Mar 24;47(4):1301–7. Available from: https://doi.org/10.1128/aac.47.4.1301-1307.2003.
[30] Getahun YA, Ali DA, Taye BW, Alemayehu YA. Multidrug-Resistant microbial therapy using antimicrobial peptides and the CRISPR/CAS9 system. Veterinary Medicine Research and Reports. 2022 Aug 1; Volume 13:173–90. Available from: https://doi.org/10.2147/vmrr.s366533.
[31] Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, et al. Considerations for the use of phage therapy in clinical practice. Antimicrobial Agents and Chemotherapy. 2022 Jan 18;66(3). Available from: https://doi.org/10.1128/aac.02071-21.
[32] Zalewska-Piątek B. Phage Therapy—Challenges, Opportunities and Future Prospects. Pharmaceuticals. 2023 Nov 22;16(12):1638. Available from: https://doi.org/10.3390/ph16121638.
[33] Cradick TJ, Fine EJ, Antico CJ, Bao G. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Research. 2013 Aug 10;41(20):9584–92. Available from: https://doi.org/10.1093/nar/gkt714.
[34] Pursey E, Sünderhauf D, Gaze WH, Westra ER, Van Houte S. CRISPR-Cas Antimicrobials: Challenges and Future Prospects. PLoS Pathogens. 2018 Jun 14;14(6):e1006990. Available from: https://doi.org/10. 1371/ journal.ppat.1006990.
[35] Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK. Genetically Engineered Phages: A Review of Advances over the Last Decade. Microbiology and Molecular Biology Reviews. 2016 Jun 2;80(3):523–43. Available from: https://doi.org/10.1128/mmbr.00069-15.
[36] Desai N. Challenges in development of Nanoparticle-Based therapeutics. The AAPS Journal. 2012 Mar 9;14(2):282–95. Available from: https://doi.org/10.1208/s12248-012-9339-4.
[37] Seaberg J, Montazerian H, Hossen MN, Bhattacharya R, Khademhosseini A, Mukherjee P. Hybrid nanosystems for biomedical applications. ACS Nano. 2021 Jan 26;15(2):2099–142. Available from: https://doi.org/10.1021/acsnano.0c09382.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
